Imbalanced expression of Bcl-xL and Bax in platelets treated with plasma from immune thrombocytopenia

被引:0
作者
Jianlin Qiao
Yun Liu
Depeng Li
Yulu Wu
Xiaoqian Li
Yao Yao
Mingshan Niu
Chunling Fu
Hongchun Li
Ping Ma
Zhenyu Li
Kailin Xu
Lingyu Zeng
机构
[1] The Affiliated Hospital of Xuzhou Medical College,Department of Hematology
[2] Xuzhou Medical College,Blood Diseases Institute
[3] Key Laboratory of Bone Marrow Stem Cell,Department of Clinical Laboratory
[4] the Affiliated Hospital of Xuzhou Medical College,undefined
来源
Immunologic Research | 2016年 / 64卷
关键词
Bcl-xL; Bax; Caspase-3; Apoptosis; Immune thrombocytopenia;
D O I
暂无
中图分类号
学科分类号
摘要
Immune thrombocytopenia is a heterogeneous autoimmune disease, characterized by accelerated platelet destruction and impaired platelet production. Bcl-xL and Bax play an opposite role in the regulation of apoptotic process with Bcl-xL for cell survival and Bax for cell apoptosis. Given the critical roles in the regulation of platelet apoptosis, whether Bcl-xL or Bax was involved in the pathogenesis of ITP remains unknown. The aim of this study is to evaluate the expression profile of Bcl-xL and Bax in platelets treated with ITP plasma. Normal washed platelets were treated with plasma from 20 active ITP patients or 10 age and gender-matched control to mimic the ITP in vivo environment. Mitochondrial depolarization, platelet apoptosis and activation were measured by flow cytometry. Expression of Bcl-xL, Bax and caspase-3 were also measured by quantitative real-time PCR and western blot. Our results demonstrated increased mitochondrial depolarization, platelet apoptosis and activation in platelets after treated with ITP plasma in comparison to control. In addition, decreased expression of Bcl-xL, increased expression of Bax and activity of caspase-3 were also observed. Furthermore, a negative correlation of Bcl-xL with Bax was found in platelets treated with ITP plasma. In conclusion, imbalanced expression of Bcl-xL and Bax might be associated with platelet apoptosis in ITP and therapeutically targeting them might be a novel approach in the treatment of ITP.
引用
收藏
页码:604 / 609
页数:5
相关论文
共 107 条
[1]  
Neunert CE(2013)Current management of immune thrombocytopenia Hematol Am Soc Hematol Educ Progr 2013 276-282
[2]  
Cines DB(2014)Pathogenesis of immune thrombocytopenia Presse Med 43 e49-e59
[3]  
Cuker A(2013)Cellular immune dysfunction in immune thrombocytopenia (ITP) Br J Haematol 163 10-23
[4]  
Semple JW(2010)A murine model of severe immune thrombocytopenia is induced by antibody- and CD8 Blood 115 1247-1253
[5]  
McKenzie CG(2010) T cell-mediated responses that are differentially sensitive to therapy Blood 115 168-186
[6]  
Guo L(2013)International consensus report on the investigation and management of primary immune thrombocytopenia Semin Hematol 50 S109-S115
[7]  
Freedman J(2007)Cell death in immune thrombocytopenia: novel insights and perspectives Cell 128 1173-1186
[8]  
Semple JW(2010)Programmed anuclear cell death delimits platelet life span Semin Hematol 47 227-234
[9]  
Chow L(2007)Apoptotic processes in megakaryocytes and platelets Cell 128 1035-1036
[10]  
Aslam R(2011)A Bcl-xL timer sets platelet life span Blood 118 1663-1674